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Abstract
Background: Left ventricular outflow tract (LVOT) obstruction and paravalvular leak (PVL) are relatively uncommon,
but are serious complications of prosthetic valve replacement.
Case presentation: We present a case that displays the unique therapeutic challenges of treating a patient who
developed both LVOT obstruction and mitral PVL after undergoing surgical aortic and mitral valve replacement
(MVR). We also describe the use of alcohol septal ablation and albumin-glutaraldehyde (BioGlue) for septal ablation
to percutaneously treat the patient’s LVOT obstruction, followed by use of an Amplatzer vascular plug for percutaneous
closure of an antero-medial mitral PVL associated with severe regurgitation.
Conclusion: Percutaneous interventional management of these entities may be considered as an initial therapeutic
option, especially in high-risk patients with significant morbidity and mortality of repeat surgical operations.
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Background
The outcome of patients with valvular heart disease has
significantly improved since valve replacement surgery
was introduced in the 1960’s. Despite technological ad-
vancements in valve function and design, prosthetic
valve replacement is associated with significant adverse
events, including valve thrombosis, thromboembolism,
bleeding, and endocarditis [1]. Paravalvular leak (PVL) is
also a well-recognized complication with a reported inci-
dence of 5–15 % in the United States [2]. However, this
may have been underestimation due to the lack of sys-
tematic screening as well as difficulty in diagnosis due to
obscured view on color flow Doppler images secondary
to annular calcifications [2]. Left ventricular outflow
tract (LVOT) obstruction is a relatively rare but serious
complication of prosthetic valve replacement, with re-
ported incidence of 4–5 % post mitral valve repair [3].
We describe a patient who presented with both PVL and
LVOT obstruction after surgical aortic and mitral valve
replacement (MVR), and share our experience of the
management of this case with percutaneous techniques
under guidance of advanced imaging modalities.
Case presentation
A 67-year-old lady with hypertension and type-2 dia-
betes mellitus was diagnosed with severe aortic and mi-
tral stenosis after a syncopal event. She subsequently
underwent surgical bioprosthetic aortic valve replace-
ment at an outside community hospital, and the reason
for a single valve surgery was unclear. Post-operatively,
transthoracic echocardiography (TTE) showed an ele-
vated trans-valvular gradient across the bioprosthetic
aortic valve. She was then referred for surgical re-
intervention of the aortic bioprosthetic valve as well as
mitral valve replacement. A few days after being dis-
charged from the hospital, she developed progressive dys-
pnea with New York Heart Association (NYHA) Class IV
symptoms along with hemolytic anemia requiring multiple
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blood transfusions. Color flow Doppler on TTE demon-
strated flow acceleration through the LVOT secondary to
obstruction with increased peak gradient of 80-mmHg
[Fig. 1a]. There was severe concentric left ventricular
hypertrophy (basal septal thickness approximately 20-
mm) [Fig. 2a]. Positioning of the bioprosthetic mitral valve
in combination with severe septal hypertrophy appeared
to be the etiology of the LVOT obstruction. During her
evaluation, real-time 3D Trans-esophageal echocardiog-
raphy (TEE) was also performed confirming the LVOT
obstruction and showing a PVL located along the antero-
medial aspect of the bioprosthetic mitral valve associated
with severe mitral regurgitation [Fig. 3].
Given the patient’s acutely decompensated clinical
state and high operative risk for “re-do” valve surgery,
the decision was made to take the patient to the cardiac
catheterization laboratory for attempted percutaneous
management of the LVOT obstruction with alcohol sep-
tal ablation (ASA). The procedure began with placement
of a temporary pacemaker through a 5 French sheath via
the right internal jugular vein approach. The left coron-
ary artery was then engaged with an EBU 3.5 guide cath-
eter (Medtronic, Danvers, MA) followed by passage of
1.5 mm × 6.0 mm over-the-wire (OTW) angioplasty bal-
loon into the first septal perforator artery using an Asahi
Prowater wire (Abbott, Abbott Park, IL) [Fig. 4a, b, and c].
The balloon was then inflated and selective angiography
was performed through the OTW balloon to confirm that
there was no extravasation of contrast into the left anter-
ior descending artery (LAD) and evaluated the area of
Fig. 1 Intra-procedural Trans-esophageal Echocardiography. a Pre-procedure continuous wave Doppler velocity tracing showing elevated gradient
across LVOT which is characteristic of dynamic outflow obstruction. b After alcohol septal ablation, continuous wave Doppler velocity still showed
elevation of gradient across LVOT. c Continuous wave Doppler velocity showing reduction in gradient across LVOT after injection of glue
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myocardium to be ablated by both angiography and myo-
cardial contrast echocardiography. Following confirmation
that the septal perforator supplied the septal myocardium
of interest, a slow injection of 2 mL of absolute alcohol
was infused over a period of 10 min. A second slow
injection of 2 mL of absolute alcohol was performed due
to a persistently elevated LVOT gradient. Despite two in-
jections of absolute alcohol, intra-procedural TEE showed
a residual peak gradient across the LVOT of 50-mmHg
[Fig. 1b]. At this point, the decision was made to inject
1 mL of BioGlue (Cryo Life, Kennesa, GA) - purified bo-
vine serum albumin and glutaraldehyde [Fig. 2b] which re-
duced the peak LVOT gradient to 25-mmHg [Fig. 1c].
After BioGlue injection, the patient developed complete
heart block and was transvenously paced for the remain-
der of the procedure, and ultimately required placement
of a dual chamber pacemaker. There was no other compli-
cation subsequent to the procedure.
After the LVOT obstruction was relieved, there was
persistence of the PVL. Despite being symptomatically
improved, she still had residual symptoms and persistent
hemolytic anemia with hemoglobin in the 8 g/dl range.
Thus, two weeks after the septal ablation, patient was
brought back to the catheterization laboratory for re-
pair of the PVL. Access was obtained in the right com-
mon femoral vein. An 8.5-French SRO guiding sheath
(St Jude Medical, Saint Paul, MN) was advanced over
the wire to the right atrium and puncture of the intera-
trial septum was performed under TEE guidance using
a Baylis trans-septal needle (Baylis Medical, Burlington,
MA). The needle was removed and a 0.032” Cook wire
(Cook, Bloomington, IN) was advanced to the left atrium.
The SRO sheath was then exchanged for an 8.5-French
Agilis catheter (St Jude Medical, Saint Paul, MN) followed
by a 6-French JR4 catheter advanced into the left atrium
through the Agilis Sheath. A 0.035” Terumo floppy
Glidewire (Terumo Interventional Systems, Somerset,
NJ) was guided across the PVL into the left ventricle.
The Agilis catheter was removed and the JR4 catheter
advanced to the left ventricle (LV). An 8 mm Amplatzer
Vascular Plug II (AVP II) (St Jude Medical, Saint Paul, MN)
was positioned across the PVL under real-time 3D-TEE
guidance and was successfully deployed [Fig. 5a and b].
Color flow Doppler on TEE confirmed reduction in mitral
Fig. 2 2-D transthoracic echocardiography. a Pre-septal ablation. b
Post-septal ablation showing septal scar and remodeling with relief
of LVOT obstruction
Fig. 3 Real-time 3-D Trans-esophageal echocardiography. 3-D Zoom view on 3-D TEE pre-deployment showing (a) antero-medial paravalvular
defect in the mitral valve (green arrow) and (b) wire passing through paravalvular leak
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regurgitation from severe to mild (Fig. 6). Post procedure,
patient continued to do well with no recurrent heart failure
symptoms, and there was resolution of hemolytic anemia.
Discussion
LVOT obstruction and PVL are recognized complica-
tions following valve replacement surgeries. However,
MVR complicated by both LVOT obstruction and PVL
has not previously been reported. Our case is unique not
only because the MVR was complicated by LVOT ob-
struction and PVL but also because both entities were
successfully treated percutaneously, avoiding the need
for repeat of high-risk surgery.
Classically, LVOT obstruction occurs in the setting of
hypertrophic obstructive cardiomyopathy, but it can also
be associated with left ventricular hypertrophy, mitral
valve abnormalities, or the use of inotropes. The narrow-
ing of left ventricular outflow tract during systole, coupled
with Venturi effect on the anterior mitral valve leaflet re-
sults in systolic anterior motion (SAM). Systolic septal
bulging into LVOT causes triad of symptoms of dyspnea,
angina and dizziness. The presence of resting obstruction,
defined as peak LVOT gradient >30 mmHg is an
important predictor for development of sudden cardiac
death or progression to heart failure [4]. Documented risk
factors that predispose patients to SAM include small left
ventricular cavities with hyperdynamic function, narrow
aorto-mitral angle, bulging left ventricular septum, and an
undersized annuloplasty ring [5, 6].
LVOT obstruction can be managed medically or inva-
sively with surgical or percutaneous methods depending
on the etiology and severity. Medical management, such
as beta-adrenoceptor blockade, volume loading, and
phenylephrine, have been reported to be sufficient in pa-
tients with mild to moderate LVOT obstruction [7].
For severe LVOT obstruction, surgical myectomy re-
mains the gold standard therapy [7]. Percutaneous
ASA may be an alternative option to relieve symptoms
due to LVOT obstruction. In this catheter-based pro-
cedure, alcohol is injected into the septal perforator
branch with the aim of creating ischemia and infarc-
tion within the septal myocardium of the LVOT. ASA
has been shown to effectively reduce the pressure gra-
dient across the left ventricular outlet tract. Dabrowski
et al. showed that in a group of patients with initial
mean LVOT peak gradient (PG) of 123 ± 33 mm Hg,
Fig. 4 Coronary angiography. Coronary angiography performed showing (a) location of the septal perforator, (b) wire in the septal and (c) balloon
inflation in the septal branch
Fig. 5 Intra-procedural Trans-esophageal echocardiography. a 3-D Zoom view on 3-D TEE post-deployment showing final position of Amplatzer
vascular plug II (blue arrow). b 4-Chamber view on 2-D TEE showing Amplatzer vascular plug in situ (red arrow)
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the pressure gradient across the LVOT decreased to
an average of 52 ± 37 mm Hg (p < 0.0001) at three
months after ASA and to 37 ± 28 mm Hg (p < 0.0001)
at six months after ASA [8]. Procedural success was
defined as ≥50 % reduction in the peak LVOT gradi-
ent observed at rest or a final residual resting gradi-
ent of <20-mmHg in the absence of death or need
for emergency surgery [9].
A meta-analysis by Agarwal et al. that compared the
outcomes of ASA and myectomy showed that ASA and
myectomy had similar mortality [10]. ASA has been as-
sociated with higher post procedure complication of
conduction abnormalities and higher post intervention
LVOT gradient compared to myectomy. There was no
significant difference in other outcomes such as post-
intervention functional status, improvement in NYHA
functional class, ventricular arrhythmia occurrence, re-
interventions performed, and post-procedure mitral re-
gurgitation [10].
Our patient was deemed to be too high risk for surgical
re-intervention. Furthermore, the presence of an aortic
prosthesis complicates surgical management of LVOT ob-
struction as surgical septal myectomy is traditionally per-
formed via the trans-aortic approach. ASA was performed
as described, but there was no adequate reduction in the
pressure gradient across the LVOT. Thus, the decision
was made to proceed with injection of BioGlue (Cryo Life,
Kennesaw, GA). BioGlue consists of purified bovine serum
albumin (BSA) and glutaraldehyde and is commonly used
as adjunct in hemostasis in open surgical repair of large
vessels. This case demonstrates the feasibility of the off-
label use of BioGlue to induce septal myocardial ischemia/
infarction in the treatment of LVOT obstruction due to
septal hypertrophy. Our patient went into complete heart
block after the injection of BioGlue requiring eventual
permanent pacemaker placement. Permanent pacemaker
is a known complication of ASA with an incidence of ap-
proximately 13–20 % [9, 11], but the incidence of bradyar-
rythmias requiring pacemaker placement after BioGlue
injection in these situations is not known. Furthermore
the safety of using BioGlue in these situations has not
been established and further studies are necessary to
evaluate its use for septal ablation in hypertrophic cardio-
myopathy, particularly in the sequential use of BioGlue
following alcohol-septal ablation.
Despite successful percutaneous management of our
patient’s LVOT obstruction, she continued to be
symptomatic from the severe mitral regurgitation as-
sociated with her PVL. Although most cases of PVLs
are asymptomatic, surgical or percutaneous repair is
indicated when it is associated with heart failure or
persistent hemolytic anemia requiring blood transfu-
sions. Surgical intervention is recommended in pa-
tients with symptomatic PVL, though reoperation is
associated with mortality rates approaching 16 % [12].
Thus, a less invasive percutaneous approach may be
an attractive alternative to open surgery. Paramitral
valvular leak can be approached via antegrade trans-
septal, retrograde transaortic, or retrograde transapical
approach. Although several studies have demonstrated
the safety and efficacy of percutaneous closure of PVL
[13], there are limited reports of this intervention in
the presence of double prosthetic valves. In a case re-
ported by David et al., they described a left ventricular
trans-apical approach to access the PVL in a patient
with double prosthetic valves [14]. In our patient, we
successfully utilized an antegrade approach via a trans-
septal puncture.
Fig. 6 Trans-esophageal echocardiography with color Doppler. Left: Pre-procedure: Antero-medial mitral paravalvular leak associated with
moderate-severe mitral regurgitation. Right: Post deployment of Amplatzer vascular plug (#red arrow) showing significant reduction of
mitral regurgitation
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Even in the presence of a single prosthetic valve, per-
cutaneous PVL repair is technically challenging and suc-
cess depends on the appropriate device selection, which
requires balance between completeness of the defect
coverage without interfering with the valve leaflets and
surrounding structures. Currently, there are no devices
designed specifically to meet the unique anatomic and
physiologic properties of PVL. Instead, devices that have
been approved for the closure of other cardiovascular
defects (e.g., patent ductus arteriosus, atrial septal defect,
ventricular septal defect) by the U.S. Food and Drug
Administration have been used in an off-label manner in
the closure of PVL. Among noted reasons for procedural
failures include prosthetic leaftlet impingement, pres-
ence of residual moderate or severe mitral regurgitation,
and inability to cross defect with delivery sheath or
guidewire [13]. Documented 30-day all-cause mortality
was 1.7 to 5.4 % [13, 15].
Due to the complexity of the procedure, real time 3-
dimensional (3-D) TEE is important to reduce proced-
ure failures. 3-D imaging allows clear visualization of
the paravalvular areas and appreciation of the spatial
location of the defect in relation to the other structures.
This facilitates navigation of the catheter and also de-
ployment of the device. Besides, the use of 3-D TEE
also allows us to detect procedural complications in
real time, as well as to assess the immediate result of
the implantation of the device.
This case demonstrates the successful use of BioGlue
for septal ablation in severe LVOT obstruction and per-
cutaneous closure of anteromedial mitral PVL via ante-
grade approach in the same patient in the presence of
bio-prosthetic mitral and aortic valves utilizing real-time
3-D TEE guidance. Surgical repair has traditionally been
considered the gold standard for management of pa-
tients with such complications. The significant morbidity
and mortality associated with repeat surgery, however, is
a major concern in these high-risk patients. More stud-
ies are needed to determine if BioGlue injection for sep-
tal ablation would be an effective alternative to alcohol
for the treatment of LVOT obstruction due to septal
hypertrophy. In terms of percutaneous PVL closure, as
more experience is gained and with the development of
specific closure devices for PVL, percutaneous closure
will become a more standard approach.
Conclusion
Percutaneous interventional management of LVOT ob-
struction and mitral PVL as a complication of surgical
aortic and mitral valve replacement may be considered
as an initial therapeutic option, especially in high-risk
patients with significant morbidity and mortality of re-
peat surgical operations.
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